Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001144204-17-051883
Filing Date
2017-10-10
Accepted
2017-10-10 16:01:30
Documents
3
Effectiveness Date
2017-10-10

Document Format Files

Seq Description Document Type Size
1 DEFA14A tv476686_defa14a.htm DEFA14A 17919
2 GRAPHIC image_001.jpg GRAPHIC 308532
3 GRAPHIC image_002.jpg GRAPHIC 133243
  Complete submission text file 0001144204-17-051883.txt   627879
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33357 | Film No.: 171130489
SIC: 2836 Biological Products, (No Diagnostic Substances)